We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by 20%), mETS (shrinkage by 0 to <20%), mPD (minor progression >0 to <20%) and PD (progression 20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8 (95% CI 11.1-14.5) months). Differences in PFS of first-line therapy were less pronounced. ETS subgroups defined in first-line therapy also correlated with efficacy of second-line therapy. Progression-free survival in second-line (PFS2nd) was 6.5 months (5.8-7.2) for ETS, and was 5.6 (95% CI 4.7-6.5) months for mETS, 4.9 (95% CI 3.7-6.1) months for mPD and 3.3 (95% CI 2.3-4.3) months for PD. PFS of first-line and PFS2nd showed a linear correlation (Bravais-Pearson coefficient: 0.16, p 5 0.006). While ETS is associated with the most favorable outcome, non-ETS represents a heterogeneous subgroup with distinct characteristics of less favorable initial tumor response to treatment. This is the first analysis to demonstrate that early tumor response observed during first-line FOLFIRI-based therapy may also relate to efficacy of second-line treatment. Early response parameters may serve as stratification factors in trials recruiting pretreated patients.
Early changes in the sum of largest diameters of target lesions (SLD) have been identified as predictors of survival in patients with metastastic colorectal cancer (mCRC). [1] [2] [3] [4] [5] [6] [7] In several firstline studies, early tumor shrinkage (ETS) was defined as shrinkage by 20% at the time of first tumor staging, typically performed at 6 to 8 weeks after start of therapy. 2, 3, 6 Although the association between ETS and OS may be more pronounced in patients receiving EGFR-targeted agents, similar observations have been made in trials (or trial-arms) without EGFR-targeted agents. 1, 4, 8 In accordance with other trials, ETS was found to correlate with favorable survival in both arms of the FIRE-3 study (FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type mCRC).
While the current definition is based on a dichotomous distinction of ETS from non-ETS patients, the latter group represents a heterogeneous population including subgroups with stable diseases and progressive disease. An increasing body of evidence supports ETS as a parameter of favorable tumor biology relating early response to maximal depth of responses and prolonged survival. 5, 9 However, only little is known on the clinical relevance and differential outcome of non-ETS subgroups. 1, 4 The present understanding is that ETS subgroups reflect initial sensitivity to treatment, which to some extent relates to the efficacy of antitumor agents employed. Initial resistance to treatment could be overcome by an appropriate switch in therapy, for example, by blockade of another signal transduction pathway.
On the other hand, initial sensitivity parameters may also reflect tumor biology in a more general sense suggesting that outcome parameters obtained during first-line therapy may also relate to results in later treatment lines. This issue can only be clarified by a comprehensive analysis of response to first-and second-line therapy.
The present explorative evaluation of FIRE-3 was first designed to investigate response parameters of ETS-and non-ETS subgroups as obtained in first-line, FOLFIRI-based treatment. In a further analysis, the question was asked how these subgroups performed in second-line treatment. Lastly, the relation between first-and second-line results as well as their impact on OS was explored in the respective subgroups.
Patients and Methods

Patient population
Independent central review of tumor assessment by experts was part of the study protocol. Results of the central response evaluation have been described and published recently. 10 The current analysis was based on the population that was evaluable for central review of the study. The subpopulation of FIRE-3 who received subsequent treatment has also been described previously. 11 The current analysis was based on the KRAS exon 2 wild-type population (ITT) and additionally on the retrospectively assessed RAS wild-type population. The data cut-off for this analysis was August 22, 2014. 
Definition of lines of therapy, treatment duration
Second-line treatment was defined as application of any new anti-cancer substance that was not part of first-line therapy, as described previously. Duration of therapy in general was defined as time from first to last application of the respective treatment, including drug holidays and re-inductions. Details concerning second-line therapy have been published recently.
11
Radiologic assessments, ETC-subgroups
The study protocol scheduled the first re-evaluation of tumors after three cycles of therapy (after 6 weeks). 12 Tumor shrinkage was analyzed at 6 weeks after initiation of treatment and was based on sum of longest diameters of target lesions (SLD). Shrinkage was classified as ETS (shrinkage by 20%), mETS (minor shrinkage by 0 to <20%), mPD (minor progression by >0 to <20%), PD (progression by 20% or new lesion). In all caculations, shrinkage was expressed as a positive denominator.
Analysis of response, progression-free survival and overall survival
Response was analyzed according to RECIST 1. Patients who benefited from first-line therapy tended to also benefit from second-line therapy, supporting a role for efficacy parameters in mCRC patient stratification.
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progression of disease or death from any cause. 12 Progressionfree survival of second-line (PFS2nd) was defined as time between first application of second-line therapy to progression or death from any cause. 11 Overall survival (OS) was defined as time from randomization to death from any cause. 12 Overall survival of second-line therapy (OS2nd) was designed as time between first application of second-line therapy and death from any cause. 11 All survival endpoints were indicated as medians.
Correlation of PFS and PFS2nd
Correlation of PFS and PFS2nd was calculated only in patients with progression prior to start of second-line therapy (331 patients of the KRAS exon 2 wild-type population, 167 arm A, 164 arm B).
Statistical analysis
Parameters of second-line therapy in this manuscript were analyzed in all patients that were eligible for central review and received at least one application of further systemic treatment following first-line therapy on study. Progression-free and overall survival data were assessed by the Kaplan-Meier method and compared with log-rank tests. Differences between groups in dichotomous variables were analyzed using two-sided Fisher's exact tests or v 2 tests (>2 groups). Median values were used to describe duration of therapy and comparisons were made using the Kruskal-Wallis-test. A multivariate analysis of PFS2nd was conducted using a Cox proportional hazards regression model with age (>65 yes vs. no), study arm, ECOG, ETS versus non-ETS, sex, primary tumor site (left-sided vs. right sided), liver-limited disease and lung-limited disease as factors. Two-sided p-values <0.05 were considered significant. All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC) and IBM SPSS Statistics 22 (IBM Corporation, Armonk, NY).
Role of the funding source
Merck KGaA and Pfizer, as supporting parties, had no role in design and conduct of this analysis, writing of the manuscript or the decision to submit and publish the data. Merck KGaA and Pfizer reviewed the manuscript prior to journal submission. Volker Heinemann had full access to all study data and had the final responsibility for publication.
Results
The ITT population of FIRE-3 comprises 592 patients with KRAS exon 2 wild-type tumors, of those 493 patients were eligible for central radiologic review. Of 400 patients with RAS wild-type tumors, 330 patients were eligible for central review of tumor assessments. Data from both populations were analyzed and described in this manuscript.
Patients
Baseline characteristics of patients and tumors are summarized in Supporting Information Table 1 .
Early tumor changes in FIRE-3
Of 493 evaluable patients with KRAS exon 2 wild-type mCRC, 270 patients (54.8%) achieved ETS and 144 patients (29.2%) achieved mETS. mPD was observed in 20 patients (4.1%) and PD in 59 patients (12.0%). Details and data on the RAS wild-type population are shown in Table 1 .
ETS and subsequent treatment
Exposition to subsequent treatment procedures according to subgroups of early tumor shrinkage and non-ETS subgroups is summarized in Supporting Information Table 2 .
Association of ETS and response to first-line therapy
In ETS-patients with KRAS exon 2 wild-type tumors, objective response (ORR) according to RECIST criteria (SLD by 30%) was reached in 90% (243/270) of patients, 93.2% in the cetuximab-arm, and 86.2% in the bevacizumab-arm. In the subgroup of mETS patients, ORR was still reached in 38.9% (56/144) of patients with a comparable frequency in both treatment arms (37.7 vs. 39.6%). In mPD patients, ORR by RECIST criteria was only observed in one out of 14 patients treated in the FOLFIRI plus bevacizumab arm. Similar data were observed for patients with RAS wild-type mCRC (see Table 2 ).
Early tumor shrinkage and PFS and OS of first-line therapy
Progression-free survival was comparable between ETS, mETS, and mPD (8.7 months). By contrast, overall survival was longest in ETS patients [33.2 (28.0-38.4) months], and markedly shorter in non-ETS subgroups such as mETS Table 2 .
ETS and treatment duration of first-line and second-line therapy
Duration of first-line therapy was significantly associated (KRAS exon 2 wild-type population: p < 0.001, RAS wild-type population: p < 0.001) with subgroups of early tumor change. Accordingly, also duration of second-line therapy was significantly associated (KRAS exon 2 wild-type population: p 5 0.015, RAS wild-type population: p 5 0.008) with subgroups of early tumor change during first-line therapy. In patients with mPD, patient numbers were small. Detailed data are shown in Figures 2a and 2b .
Association of ETS with response to second-line treatment
In patients with KRAS exon 2 wild-type tumors, response to second-line therapy was more frequently seen in patients that had achieved ETS in first-line therapy (47/1925 24.5%) than in patients with mETS (12/1035 11.7%) and PD (4/445 9.1%). In patients with mPD (3/115 27.3%) numbers were small. Data were similar for treatment arms and in the RAS wild-type population, see Table 2 .
Influence of ETS on PFS2nd and OS2nd
In patients with KRAS exon 2 wild-type mCRC, subgroups of early tumor change were associated with distinct outcomes for PFS2nd (p < 0.0001). ETS and mETS in first-line therapy was followed by favorable PFS2 in second-line therapy. A similar observation was made for OS2nd (p < 0.0001). Detailed data and RAS wild-type patients are shown in Figures 1c, 1d and Supporting Information Figures. Data concerning outcome in the two treatment arms are summarized in Table 2 . The impact of ETS versus non ETS as a factor for PFS2nd was also evaluated within a multivariate Cox model:
in both populations, ETS remained an significant factor for PFS2nd. Details are summarized in Table 3 .
Correlation of PFS and PFS2nd
A weak, but significant, positive correlation of PFS and PFS2nd was evident in patients with KRAS exon 2 wild-type tumors (coefficient 0.16, p 5 0.004). Correlations in study arms and RAS-data are summarized in Table 4 Discussion This investigation was designed to explore the impact of ETS and different non-ETS subgroups on outcome of patients with mCRC in FIRE-3. A special focus of this manuscript was to explore the heterogeneity of patients with non-ETS after 6 weeks of combination therapy. In FIRE-3, ETS and non-ETS subgroups were associated with distinct outcomes of patients in both arms during first-line therapy. While ETS correlated with high response rates, consecutive favorable PFS times and OS beyond 30 months, the outcome in patients with mETS was characterized by moderate response rate, similar PFS as compared to ETS-patients and OS of about two years. These data could indicate that besides the established early indicator of favorable outcome (ETS), 3, 13 mETS also describes patients with treatment-sensitive tumors, that may benefit less than patients with ETS, but still enough to justify treatment continuation with a three-drug regimen. It could be hypothesized that mETS contains slow responding tumors that still react to systemic therapy. By contrast, minor progression (mPD) still categorized as stable disease by RECIST correlated with an acceptable PFS of about 8 months and translated into OS of <20 months in both arms of FIRE-3. mPD could accordingly be characterized as slow progressing tumors. It might also be speculated that mPD contains subpopulations of patients that still somehow benefit from therapy as indicated by the PFS, but on the other hand patients that present with rather refractory tumors after failure of first-line therapy. Patients with progressing tumors according to RECIST (PD) after 6 weeks of treatment presented with unfavorable OS of about one year only, this observation compares well to previous evaluations. As some subgroups (i.e., progressing tumors) may require early change of treatment after failure of first-line therapy, second-line therapy, as the remaining key determinant of survival in affected patients, was also investigated. Interestingly, the correlation of categories of first-line treatment-related ETS and non-ETS with efficacy of treatment was also observed in second-line therapy. In patients with favorable outcome during first-line therapy, clinical benefit from second-line therapy was also evident, underlined by long treatment-courses of secondline treatment as well as favorable PFS2nd and OS2nd. Despite early need to change the strategy of treatment in PD-patients, frequency of second-line and third-line therapy was similar compared to those patients that were likely to remain on firstline therapy for a long duration of time (i.e., patients with ETS or mETS). It might be suspected that unfavorable tumor dynamics might have prevented some patients with initial PD to receive salvage therapy. Moreover, those patients with early PD that received second-line regimens experienced short courses of second-line therapy, leading to modest efficacy of the respective regimens. Of note, although limited by sample size, second-line treatments in mPD-patients seemed to succeed rather in cetuximab-than in bevacizumab-pretreated patients.
Although the association of first-line ETS-and non ETS groups with second-line efficacy was less striking as compared to first-line efficacy, the evaluation of second-line therapy may suggest that sensitivity to systemic treatment as a characteristic of a tumor biology is preserved during multiple lines of treatment and well-doing patients continue treatment beyond firstline therapy with satisfying efficacy of second-line therapy. This finding was confirmed with a multivariate Cox model in which first-line ETS remained a significant factor for PFS2nd.
On the contrary, in patients experiencing early failure of first-line therapy, efficacy signals in second-line therapy are not striking despite few responses and hypothesized differences between treatment-arms. An alternative explanation for the association between successful first-and secondline therapy could be that first-line treatment sensitizes tumors to second-line therapy 14 and creates a favorable precondition for the consecutive line of therapy. In support of this assumption, a significantly positive correlation of PFS and PFS2nd was seen in FIRE-3. Therefore, it may be hypothesized that tumor biology and efficacy of first-line therapy play an important role for the outcome of patients receiving salvage therapy. In addition, these observations provide an additional explanation for previous findings that exposure to specific second-line substances per se does not necessarily correlate with OS. 11 Our finding support the use of efficacy-parameters (i.e., response, PFS) as stratification factors (especially in trials with limited sample size). In fact, this has been used by some recent trials. [15] [16] [17] This investigation is limited by the retrospective use of a post-randomization factor (early tumor change) and by the limited sample size, especially in patients of the rather unfavorable non-ETS subgroups. The second-line therapy was conducted in a nonrandomized fashion and also selection of subsequent therapies was based on the choice of local investigators. This setting, although allowing for a continuous observation of patients across multiple lines of therapy, may introduce a bias that cannot be excluded in the present analysis. As our observations base on a FOLFIRI-treated cohort, no conclusions concerning other chemotherapy backbones can be made.
In conclusion, this manuscript suggests that ETS and non-ETS subgroups are associated with differing efficacy of firstline, FOLFIRI-based treatment in patients with KRAS exon 2 wild-type tumors and moreover that non-ETS comprises patients with and without clinical benefit from first-line combination-therapy. Furthermore, the effects of early tumor change on survival of patients are also mediated by ETS-and Legend: The linear association of first-line PFS and PFS2nd was tested in patients with progression prior to second-line therapy. A coefficient of 21 indicates: the shorter first-line PFS is, the longer is PFS2nd. A coefficient of 1 indicates: the longer first-line PFS is, the longer is PFS2nd.
non-ETS associated effects observed during consecutive second-line therapy. While ETS represents a favorable subgroup of patients, mETS and mPD could be interpreted as associated to tumors with slower dynamics compared to clearly responding (ETS) or progressive patients (PD). Efficacy of first-line therapy should be considered as important stratification-factor in studies investigating later-line treatment for metastatic colorectal cancer.
